Efficacy and safety of a bFGF inhibitor,tadenan in the treatment of benign prostatic hyperplasia:a multicenter trial in China
- VernacularTitle:碱性成纤维细胞生长因子抑制剂太得恩治疗良性前列腺增生
- Author:
Jie JIN
;
Hua MEI
;
Yuanfang ZHANG
;
Al ET
- Publication Type:Journal Article
- Keywords:
Prostatic hyperplasia;
Fibroblast growth factor,basic;
Tadenan
- From:
Chinese Journal of Urology
2000;0(01):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To further confirm the Efficacy and safety of tadenan (Pygeum africunum extract) in the treatment of benign prostatic hyperplasia (BPH) in larger population in China. Methods In this open multicenter study,a total of 3 508 patients with symptomatic BPH received oral tadenan of 50 mg twice daily for 8 weeks. Results IPSS,maximum urinary flow and post voiding volume were 19.57? 14.93 ,(13.52?5.36)ml/s and (44.58?30.95)ml four weeks after the treatment of tadenan and were 13.31?11.86,(15.58?5.98)ml/s and (32.64?24.23)ml eight weeks after the treatment,both improved significantly comparing to those before the treatment ( P
